$CADL
Candel Therapeutics, Inc.

2021 Q4 Form 10-Q Financial Statement

#000095017021004274 Filed on November 12, 2021

View on sec.gov

Income Statement

Concept 2021 Q4 2021 Q3 2020 Q3
Revenue $31.00K $31.00K $31.00K
YoY Change 0.0% 0.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $3.917M $2.795M $967.0K
YoY Change 49.39% 189.04%
% of Gross Profit
Research & Development $3.854M $5.265M $1.813M
YoY Change 9.18% 190.4%
% of Gross Profit
Depreciation & Amortization $178.0K $21.00K $53.00K
YoY Change 2866.67% -60.38%
% of Gross Profit
Operating Expenses $7.771M $8.060M $2.780M
YoY Change 26.23% 189.93%
Operating Profit -$8.029M -$2.749M
YoY Change 192.07%
Interest Expense -$11.00K -$14.00K $41.00K
YoY Change -122.45% -134.15%
% of Operating Profit
Other Income/Expense, Net $9.347M -$8.133M $195.0K
YoY Change -312.34% -4270.77%
Pretax Income $1.596M -$16.16M -$2.554M
YoY Change -115.23% 532.81%
Income Tax $0.00
% Of Pretax Income
Net Earnings $1.596M -$16.16M -$2.554M
YoY Change -115.23% 532.81%
Net Earnings / Revenue 5148.39% -52135.48% -8238.71%
Basic Earnings Per Share -$0.69
Diluted Earnings Per Share $55.50K -$692.9K -$91.88K
COMMON SHARES
Basic Shares Outstanding 28.69M 28.69M
Diluted Shares Outstanding 23.33M

Balance Sheet

Concept 2021 Q4 2021 Q3 2020 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $82.64M $88.39M
YoY Change
Cash & Equivalents $82.64M $88.39M $18.52M
Short-Term Investments
Other Short-Term Assets $2.303M $2.565M
YoY Change
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $84.95M $90.95M
YoY Change 141.69%
LONG-TERM ASSETS
Property, Plant & Equipment $3.836M $4.587M
YoY Change 37.64%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $424.0K $423.0K
YoY Change 21.49%
Total Long-Term Assets $4.260M $5.010M
YoY Change 35.84%
TOTAL ASSETS
Total Short-Term Assets $84.95M $90.95M
Total Long-Term Assets $4.260M $5.010M
Total Assets $89.21M $95.96M
YoY Change 133.02%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.590M $925.0K
YoY Change 72.64%
Accrued Expenses $3.438M $3.243M
YoY Change 9.42%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $5.362M $4.397M
YoY Change 13.77%
LONG-TERM LIABILITIES
Long-Term Debt $560.0K $541.0K
YoY Change
Other Long-Term Liabilities $19.15M $28.04M
YoY Change
Total Long-Term Liabilities $19.71M $28.58M
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $5.362M $4.397M
Total Long-Term Liabilities $19.71M $28.58M
Total Liabilities $25.07M $32.97M
YoY Change 96.09%
SHAREHOLDERS EQUITY
Retained Earnings -$80.30M -$81.89M
YoY Change 81.78%
Common Stock $144.4M $144.9M
YoY Change 600.82%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $64.14M $62.99M -$14.82M
YoY Change
Total Liabilities & Shareholders Equity $89.21M $95.96M
YoY Change 133.02%

Cashflow Statement

Concept 2021 Q4 2021 Q3 2020 Q3
OPERATING ACTIVITIES
Net Income $1.596M -$16.16M -$2.554M
YoY Change -115.23% 532.81%
Depreciation, Depletion And Amortization $178.0K $21.00K $53.00K
YoY Change 2866.67% -60.38%
Cash From Operating Activities -$5.238M -$6.894M -$3.441M
YoY Change 53.34% 100.35%
INVESTING ACTIVITIES
Capital Expenditures -$504.0K -$392.0K -$1.023M
YoY Change 11.26% -61.68%
Acquisitions
YoY Change
Other Investing Activities $0.00 $0.00 $14.00K
YoY Change -100.0% -100.0%
Cash From Investing Activities -$504.0K -$392.0K -$1.009M
YoY Change -102.5% -61.15%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 71.36M 460.0K
YoY Change -100.0% 15411.96%
NET CHANGE
Cash From Operating Activities -5.238M -6.894M -3.441M
Cash From Investing Activities -504.0K -392.0K -1.009M
Cash From Financing Activities 0.000 71.36M 460.0K
Net Change In Cash -5.742M 64.07M -3.990M
YoY Change -134.19% -1705.74%
FREE CASH FLOW
Cash From Operating Activities -$5.238M -$6.894M -$3.441M
Capital Expenditures -$504.0K -$392.0K -$1.023M
Free Cash Flow -$4.734M -$6.502M -$2.418M
YoY Change 59.77% 168.9%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2021Q3 us-gaap Preferred Stock Value
PreferredStockValue
CY2021Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021Q3 us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
one-for-2.4579
CY2020Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2020Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2021Q3 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.407
dei Entity Central Index Key
EntityCentralIndexKey
0001841387
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Amendment Flag
AmendmentFlag
false
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2021-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2021
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-40629
dei Entity Registrant Name
EntityRegistrantName
CANDEL THERAPEUTICS, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
52-2214851
dei Entity Address Address Line1
EntityAddressAddressLine1
117 Kendrick St
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 450
dei Entity Address City Or Town
EntityAddressCityOrTown
Needham
dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02494
dei City Area Code
CityAreaCode
617
dei Local Phone Number
LocalPhoneNumber
916-5445
dei Security12b Title
Security12bTitle
Common Stock, par value $0.01 per share
dei Trading Symbol
TradingSymbol
CADL
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Shell Company
EntityShellCompany
false
CY2020Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
187000
CY2020Q4 cadl Paycheck Protection Program Loan Current
PaycheckProtectionProgramLoanCurrent
463000
CY2021Q3 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
554000
CY2020Q4 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
632000
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3142000
CY2021Q3 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
229000
CY2021Q3 us-gaap Long Term Debt
LongTermDebt
541000
CY2020Q4 us-gaap Long Term Debt
LongTermDebt
483000
CY2021Q3 cadl Warrant Liability Noncurrent
WarrantLiabilityNoncurrent
27450000
CY2020Q4 cadl Warrant Liability Noncurrent
WarrantLiabilityNoncurrent
6831000
CY2021Q3 us-gaap Liabilities
Liabilities
32973000
dei Entity Bankruptcy Proceedings Reporting Current
EntityBankruptcyProceedingsReportingCurrent
true
CY2021Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
28689842
CY2021Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
88385000
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
35053000
CY2021Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2565000
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
93000
CY2020Q4 us-gaap Liabilities
Liabilities
12784000
CY2021Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2021Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2021Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q3 us-gaap Assets Current
AssetsCurrent
90950000
CY2020Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2020Q4 us-gaap Assets Current
AssetsCurrent
35146000
CY2021Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
4587000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2787000
CY2021Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
423000
CY2020Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
349000
CY2021Q3 us-gaap Assets
Assets
95960000
CY2020Q4 us-gaap Assets
Assets
38282000
CY2021Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
925000
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
921000
CY2021Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3243000
CY2021Q3 us-gaap Liabilities Current
LiabilitiesCurrent
4397000
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
4713000
CY2021Q3 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
31000
CY2020Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
125000
CY2021Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2020Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2021Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
75000000
CY2021Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
28689842
CY2021Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
28689842
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
11635094
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
11635094
CY2021Q3 us-gaap Common Stock Value
CommonStockValue
286000
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
116000
CY2021Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
144592000
CY2020Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
20493000
CY2021Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-81891000
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-44171000
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
62987000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
-23562000
CY2021Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
95960000
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
38282000
CY2021Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
31000
CY2020Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
31000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
94000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
94000
CY2021Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5265000
CY2020Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1813000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
11324000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5220000
CY2021Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2795000
CY2020Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
967000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6756000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2559000
CY2021Q3 us-gaap Operating Expenses
OperatingExpenses
8060000
CY2020Q3 us-gaap Operating Expenses
OperatingExpenses
2780000
us-gaap Operating Expenses
OperatingExpenses
18080000
us-gaap Operating Expenses
OperatingExpenses
7779000
CY2021Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-8029000
CY2020Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-2749000
us-gaap Operating Income Loss
OperatingIncomeLoss
-17986000
us-gaap Operating Income Loss
OperatingIncomeLoss
-7685000
CY2021Q3 us-gaap Nonoperating Gains Losses
NonoperatingGainsLosses
131000
CY2020Q3 us-gaap Nonoperating Gains Losses
NonoperatingGainsLosses
154000
us-gaap Nonoperating Gains Losses
NonoperatingGainsLosses
927000
us-gaap Nonoperating Gains Losses
NonoperatingGainsLosses
473000
CY2021Q3 us-gaap Investment Income Net
InvestmentIncomeNet
-14000
CY2020Q3 us-gaap Investment Income Net
InvestmentIncomeNet
41000
us-gaap Investment Income Net
InvestmentIncomeNet
-42000
us-gaap Investment Income Net
InvestmentIncomeNet
62000
CY2021Q3 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
8250000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
20619000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
52000
CY2021Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-8133000
CY2020Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
195000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-19734000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
483000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-16162000
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-2554000
us-gaap Net Income Loss
NetIncomeLoss
-37720000
us-gaap Net Income Loss
NetIncomeLoss
-7202000
CY2020Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-4000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
69000
CY2021Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-16162000
CY2020Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-2558000
CY2020Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.22
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-2.42
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
62987000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-37720000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-7133000
CY2021Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.69
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
69000
us-gaap Net Income Loss
NetIncomeLoss
-7202000
CY2020Q3 us-gaap Stockholders Equity
StockholdersEquity
-14816000
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
-12341000
CY2020Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
83000
CY2020Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-4000
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-2554000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-422000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
123000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-94000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-94000
cadl Increase Decrease In Deferred Rent
IncreaseDecreaseInDeferredRent
-36000
cadl Increase Decrease In Deferred Rent
IncreaseDecreaseInDeferredRent
96000
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.62
CY2021Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
23325716
CY2020Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
11614754
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
15579267
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
11614616
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
-23562000
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
35000
cadl Stock Issued During Period Value Warrant Exercised
StockIssuedDuringPeriodValueWarrantExercised
430000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2564000
us-gaap Adjustments To Additional Paid In Capital Mark To Market
AdjustmentsToAdditionalPaidInCapitalMarkToMarket
845000
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
71335000
us-gaap Net Income Loss
NetIncomeLoss
-37720000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
-43175000
CY2021Q3 cadl Stock Issued During Period Value Warrant Exercised
StockIssuedDuringPeriodValueWarrantExercised
20000
CY2021Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1314000
CY2021Q3 us-gaap Adjustments To Additional Paid In Capital Mark To Market
AdjustmentsToAdditionalPaidInCapitalMarkToMarket
595000
CY2021Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
71335000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-16162000
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
62987000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
-8038000
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
134000
us-gaap Adjustments To Additional Paid In Capital Mark To Market
AdjustmentsToAdditionalPaidInCapitalMarkToMarket
220000
CY2020Q3 us-gaap Stockholders Equity
StockholdersEquity
-14816000
us-gaap Profit Loss
ProfitLoss
-37720000
us-gaap Profit Loss
ProfitLoss
-7202000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
54000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
85000
us-gaap Share Based Compensation
ShareBasedCompensation
3409000
us-gaap Share Based Compensation
ShareBasedCompensation
354000
cadl Non Cash Interest Expense
NonCashInterestExpense
58000
cadl Non Cash Interest Expense
NonCashInterestExpense
49000
cadl Paycheck Protection Program Loan Forgiveness
PaycheckProtectionProgramLoanForgiveness
463000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
20619000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
52000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
2472000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-55000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
4000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
827000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1023000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-1331000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
18273000
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
88808000
CY2020Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
18524000
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
28000
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
81000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
523000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
69000
cadl Number Of Product Candidates
NumberOfProductCandidates
2
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-83000
us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
71335000
cadl Proceeds From Paycheck Protection Program Loan
ProceedsFromPaycheckProtectionProgramLoan
460000
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
430000
us-gaap Net Income Loss
NetIncomeLoss
-37720000
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-17680000
CY2021Q3 us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
one-for-2.4579
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-16980000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-5655000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
35000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
1000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
71800000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
461000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
53489000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
13079000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
35319000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
5445000
CY2020Q4 us-gaap Restricted Cash
RestrictedCash
266000
us-gaap Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
19296000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1331000
CY2021Q3 us-gaap Restricted Cash
RestrictedCash
423000
CY2020Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1198000
us-gaap Use Of Estimates
UseOfEstimates
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Use of estimates</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The preparation of the Company’s condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, and related disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenue and expenses during the reporting period. On an ongoing basis, the Company’s management evaluates its estimates, which include but are not limited to management’s judgments of the useful life of fixed assets, accrued expenses, fair value of common stock prior to the IPO, valuation of share-based awards, valuations of warrants, fair value of debt and income taxes. Actual results could differ from those estimates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Prior to the IPO, the Company utilized significant estimates and assumptions in determining the fair value of its common stock. The Company has utilized various valuation methodologies in accordance with the framework of the American Institute of Certified Public Accountants Technical Practice Aid, Valuation of Privately-Held Company Equity Securities Issued as Compensation (the Practice Aid), to estimate the fair value of its common stock and warrants. Each valuation methodology includes estimates and assumptions that require the Company’s judgment. These estimates and assumptions include a number of objective and subjective factors, including external market conditions, the prices at which the Company sold shares of preferred stock, the superior rights and preferences of securities senior to the Company’s common stock at the time of, and the likelihood of, achieving a liquidity event, such as an initial public offering or sale. Significant changes to the key assumptions used in the valuations could result in different fair values of common stock at each valuation date.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
CY2021Q3 cadl Accrued Third Party Research And Development Expenses Current
AccruedThirdPartyResearchAndDevelopmentExpensesCurrent
1035000
CY2021Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
543000
CY2020Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
645000
CY2021Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3243000
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Concentrations of credit risk</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash and cash equivalents and marketable securities. Periodically, the Company maintains deposits and investments in accredited financial institutions in-excess of the federally insured limits. The Company deposits its cash in financial institutions with a high credit quality and has not experienced any losses on such accounts and does not believe it is exposed to any unusual credit risk beyond the normal risk associated with commercial banking relationships.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p>
CY2021Q3 us-gaap Deferred Costs
DeferredCosts
0
CY2020Q4 us-gaap Deferred Costs
DeferredCosts
83000
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3142000
CY2020Q4 cadl Accrued Third Party Research And Development Expenses Current
AccruedThirdPartyResearchAndDevelopmentExpensesCurrent
1299000
CY2021Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
4775000
CY2020Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
2921000
CY2021Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
188000
CY2020Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
134000
CY2021Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
4587000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2787000
CY2021Q3 us-gaap Depreciation And Amortization
DepreciationAndAmortization
22000
CY2020Q3 us-gaap Depreciation And Amortization
DepreciationAndAmortization
44000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
54000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
85000
CY2021Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1665000
CY2020Q4 us-gaap Temporary Equity Shares Authorized
TemporaryEquitySharesAuthorized
17187676
us-gaap Conversion Of Stock Shares Converted1
ConversionOfStockSharesConverted1
7066398
CY2021Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2021Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2021Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2021Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
75000000
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2021Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
28689842
CY2021Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
28689842
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
11635094
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
11635094
CY2021Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
31000
CY2020Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
31000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
94000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
94000
CY2021Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1909000
CY2020Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
83000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3409000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
354000
CY2021Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Share Based Awards Other Than Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
5929000
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y6M14D
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
1966420
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
4013311
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
1.52
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
720211
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
5.91
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
14279
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
1.55
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
24410
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
1.46
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
4694833
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
2.20
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
1688516
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
1.82
CY2021Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
3006317
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue
2.41
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.8380
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
cadl Share Based Compensation Arrangement By Share Based Payment Award Waited Average Assumptions Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardWaitedAverageAssumptionsExercisePrice
1.55
CY2021Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
5804000
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
6858000
CY2020Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
1000
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
4000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
12174061
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
15619977
CY2021Q3 us-gaap Lessee Operating Lease Term Of Contract
LesseeOperatingLeaseTermOfContract
P7Y
us-gaap Loss Contingency Loss In Period
LossContingencyLossInPeriod
0
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-16162000
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-2554000
us-gaap Net Income Loss
NetIncomeLoss
-37720000
us-gaap Net Income Loss
NetIncomeLoss
-7202000
CY2021Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
23325716
CY2020Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
11614754
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
15579267
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
11614616
CY2021Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.69
CY2020Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.22
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-2.42
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.62
CY2021Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
12174061
CY2020Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
15619977

Files In Submission

Name View Source Status
0000950170-21-004274-index-headers.html Edgar Link pending
0000950170-21-004274-index.html Edgar Link pending
0000950170-21-004274.txt Edgar Link pending
0000950170-21-004274-xbrl.zip Edgar Link pending
cadl-20210930.htm Edgar Link pending
cadl-20210930.xsd Edgar Link pending
cadl-20210930_cal.xml Edgar Link unprocessable
cadl-20210930_def.xml Edgar Link unprocessable
cadl-20210930_htm.xml Edgar Link completed
cadl-20210930_lab.xml Edgar Link unprocessable
cadl-20210930_pre.xml Edgar Link unprocessable
cadl-ex31_1.htm Edgar Link pending
cadl-ex31_2.htm Edgar Link pending
cadl-ex32_1.htm Edgar Link pending
cadl-ex32_2.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending